Corvus Pharmaceuticals
CRVS
Market cap $215M

3.35 USD

-0.58

14.76%

At close Mar 26, 4:00 PM EDT

After hours

3.45

+0.10

2.99%

1 day

-14.76%

5 days

-22.81%

1 month

-19.28%

3 months

-36.67%

6 months

-34.18%

Year to date

-38.31%

1 year

90.34%

5 years

43.78%

10 years

-76.49%

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 7,390 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

300% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 8

142% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 12

100% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]

53% more call options, than puts

Call options by funds: $15.5M | Put options by funds: $10.1M

37% more funds holding

Funds holding: 62 [Q3] → 85 (+23) [Q4]

27% more capital invested

Capital invested by funds: $159M [Q3] → $202M (+$42.8M) [Q4]

10.56% more ownership

Funds ownership: 48.08% [Q3] → 58.64% (+10.56%) [Q4]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$11

228%

upside

Avg. target

$13

288%

upside

High target

$15

348%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

Oppenheimer Jeff Jones 8% 1-year accuracy 3 / 37 met price target	348%upside $15	Outperform Maintained	26 Mar 2025
HC Wainwright & Co. Sean Lee 60% 1-year accuracy 15 / 25 met price target	228%upside $11	Buy Reiterated	26 Mar 2025

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about CRVS published over the past 30 days

Corvus Pharmaceuticals, Inc. (CRVS) Q4 2024 Earnings Call Transcript

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q4 2024 Earnings Conference Call March 25, 2025 4:30 PM ET Company Participants Zack Kubow - Real Chemistry, IR Leiv Lea - CFO Richard Miller - CEO Conference Call Participants Jeff Jones - Oppenheimer Aydin Huseynov - Ladenburg Thalmann Cha Cha Yang - Jefferies Daniel Bronder - Cantor Sean Lee - H.C. Wainwright Operator Good afternoon, everyone.

Corvus Pharmaceuticals, Inc. (CRVS) Q4 2024 Earnings Call Transcript

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Data From Cohorts 1-3 anticipated to be Presented in May Initial Results From First Two Cohorts Supports Safety and Efficacy with Oral Agent and Novel Mechanism of Action Registration Phase 3 Clinical Trial of Soquelitinib in Peripheral T Cell Lymphoma (PTCL) Enrolling with Multiple Clinical Sites Open Conference call today at 4:30 p.m. ET / 1:30 p.m.

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma

Data to be presented in oral session and poster at the 16th Annual T-Cell Lymphoma Forum Data to be presented in oral session and poster at the 16th Annual T-Cell Lymphoma Forum

Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma

Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

SOUTH SAN FRANCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and participate in a fireside chat presentation at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference, which is being held virtually. The fireside chat will be on Thursday, March 27, 2025 at 12:00 pm ET.

Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)

Trial for this rare genetic disease to be conducted by NIH/NIAID in partnership with Corvus ITK inhibition intended to address dysregulation of T cells that causes ALPS and has been shown to be effective at treating the disease in preclinical models BURLINGAME, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has initiated a Phase 2 clinical trial of soquelitinib for the treatment of patients with autoimmune lymphoproliferative syndrome (ALPS), a rare genetic disease.

Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)

Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

BURLINGAME, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, which is being held virtually. The presentation will be on Tuesday, February 11, 2025 at 9:20 am ET.

Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Data continue to demonstrate a favorable safety and efficacy profile, including improvements in IGA 0 or 1 and EASI 75 scores compared to placebo Data continue to demonstrate a favorable safety and efficacy profile, including improvements in IGA 0 or 1 and EASI 75 scores compared to placebo

Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

BURLINGAME, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer, will conduct one-on-one meetings with investors and present a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference, which is being held in San Francisco from January 13-16, 2025. The Company's presentation will be on Wednesday, January 15 at 2:15 pm ET / 11:15 am PT.

Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Corvus Pharmaceuticals: Not Just A One-Hit Wonder In ITK Inhibitor Targeting

Positive results released from phase 1 study, using 100 mg twice daily oral dosing soquelitinib for the treatment of patients with Atopic Dermatitis; Several other cohorts testing higher dosing. The global atopic dermatitis market size is projected to reach $22.6 billion by 2031. Corvus is developing next-generation ITK inhibitors which are going to offer a more tailored approach to targeting specific immunological disorders.

Corvus Pharmaceuticals: Not Just A One-Hit Wonder In ITK Inhibitor Targeting

See News Rankings

Charts implemented using Lightweight Charts™